Mechanisms of erythropoietin‐mediated cardioprotection during ischemia‐reperfusion injury: role of protein kinase C and phosphatidylinositol 3‐kinase signaling
Authors:
Open Access
- 9 June 2005
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 19 (10) , 1323-1325
Abstract
Langendorff‐perfused rat hearts treated with EPO exhibited significantly improved postischemic recovery of left ventricular developed pressure (LVDP) and reduced infarct size compared with control hearts. Perfusion with the mitogen/extracellular signal‐regulated kinase (MEK) inhibitor U0126 just before and concomitant with EPO treatment abolished EPO‐induced phosphorylation of the MEK substrate extracellular signal‐regulated kinase (ERK) but had no effect of EPO‐mediated cardioprotection. EPO treatment of the perfused hearts induced translocation of protein kinase C (PKC) ε isoform to the membrane fraction of the hearts and the protective effect of EPO was significantly inhibited by the PKC catalytic inhibitor chelerythrine added before and concomitant with EPO. These data demonstrate that EPO‐mediated activation of the PKC signaling pathway before or during ischemia is required for the cardioprotective effect of EPO during ischemia‐reperfusion injury. Perfusion with the phosphatidylinositol 3‐kinase (PI3K) inhibitors LY294002 or wortmannin just before and concomitant with EPO treatment attenuated EPO‐induced phosphorylation of the PI3K substrate Akt but had no effect on EPO‐mediated cardioprotection. However, when wortmannin was added during EPO treatment and continued during reperfusion, EPO‐mediated cardioprotection was significantly inhibited. We also show that postischemia EPO treatment at the onset of reperfusion significantly improved recovery of LVDP and reduced infarct size. Postischemia cardioprotection by EPO required the PI3K pathway but was not affected by inhibition of PKC at the time of EPO treatment.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R21 DK‐065065)
- National Heart, Lung, and Blood Institute (HL‐39752)
- National Institute of Environmental Health Sciences
This publication has 43 references indexed in Scilit:
- Activation of Protein Kinase C Contributes to the Isoflurane-Induced Improvement of Functional and Metabolic Recovery in Isolated Ischemic Rat HeartsAnesthesia & Analgesia, 2004
- Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia‐reperfusion injuryThe FASEB Journal, 2004
- Mechanisms of Erythropoietin-induced Brain Protection in Neonatal Hypoxia-Ischemia Rat ModelJournal of Cerebral Blood Flow & Metabolism, 2004
- Isoform-specific induction of PKC-ε by high glucose protects heart-derived H9c2 cells against hypoxic injuryBiochemical and Biophysical Research Communications, 2003
- Hearts From Rodents Exposed to Intermittent Hypoxia or Erythropoietin Are Protected Against Ischemia-Reperfusion InjuryCirculation, 2003
- Ischemia-Induced Translocation of Protein Kinase C-.EPSILON. Mediates Cardioprotection in the Streptozotocin-Induced Diabetic RatCirculation Journal, 2003
- Expression of Activated PKC Epsilon (PKC ϵ) Protects the Ischemic Heart, without Attenuating Ischemic H+ ProductionJournal of Molecular and Cellular Cardiology, 2002
- Preconditioning Enhanced Glucose Uptake Is Mediated by p38 MAP Kinase Not by Phosphatidylinositol 3-KinaseJournal of Biological Chemistry, 2000
- Evidence that Translocation of Protein Kinase C is a Key Event During Ischemic Preconditioning of Rabbit MyocardiumJournal of Molecular and Cellular Cardiology, 1994
- Chelerythrine is a potent and specific inhibitor of protein kinase CBiochemical and Biophysical Research Communications, 1990